Good morning. Here's what's going right.

🌟 Today's Lead

Gene Therapy Restores Hearing in Weeks

For millions born with genetic deafness, the world has always been silent. That is changing faster than anyone predicted. The CHORD trial has demonstrated that a single injection delivering a working copy of the otoferlin gene can restore hearing in patients with OTOF-related deafness — often within just weeks of treatment.

This isn't merely an incremental improvement. Patients in the trial regained not just sound detection, but speech perception and the ability to localise sound sources — capabilities essential for navigating the hearing world. The therapy uses a harmless viral vector to deliver the gene directly to the inner ear, where it enables hair cells to transmit auditory signals to the brain.

What makes this story particularly powerful is the speed of transformation. Previous interventions often required years of rehabilitation. Here, patients report meaningful hearing improvements within weeks — a timeline that fundamentally alters the calculus for families considering treatment.